Cybin (CYBN.NE) announced it has filed their 13th provisional patent application and is building out its digital therapeutics strategy….
CYBN.NE
Cybin (CYBN.NE) announced it has filed their 13th provisional patent application and is building out its digital therapeutics strategy. Cybin did not go into detail about the patent application,…
Pubco failure Microdosing was the biggest buzzword in the psychedelics sector only 2 years ago, but nowadays it’s rarely discussed, at least in terms of publicly traded companies. HAVN…
Cybin (CYBN.NE) announced today that it has completed its 51st pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (IND)-enabling studies. Read Full…
Cybin (CYBN.NE) announced that their wholly-owned subsidiary, Adelia Therapeutics, has achieved certain earn-out milestones for the period commencing January 1, 2021. The terms of the milestone earnings were agreed…
Cybin (CYBN.NE) has selected social anxiety disorder (SAD) and generalized anxiety disorder (GAD) as the targets for their CYB004 proprietary psychedelic molecule. Read full article here: https://equity.guru/2021/06/16/cybin-cybn-ne-selects-sad-and-gad-as-targets-for-their-cyb004-psychedelic-molecule/…
Cybin (CYBN.NE) announced today that it has completed its 51st pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (IND)-enabling studies. “These experiments…
Cybin (CYBN.NE) has selected social anxiety disorder (SAD) and generalized anxiety disorder (GAD) as the targets for their CYB004 proprietary psychedelic molecule. Cybin demonstrated their proof of concept for…
In the cannabis sector, there is a wide net of different types of companies from growers to extractors to logistics & tech and everything in-between. In the earlier days…
PTSD is fascinating in that two people can have identical experiences, one can largely forget the experience while the other is in for a lifetime of suffering. What…